Your nervous system is a key force behind so many important bodily functions. But when your peripheral nerves—those found outside of the brain and spinal cord—are damaged, it can cause pain and ...

If approved by the EC, Wainzua would be the only approved medicine for the treatment of ATTRv-PN in the EU able to be self-administered with an autoinjector on a monthly basis. “Due to the progressive ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral ... the other studies and the clinical presentation to suggest a diagnosis of CIDP. Once ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...

000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Having additional amyloidosis treatment options designed to reduce the production of TTR protein at its ... Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, said: ...

for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. “Today marks another important milestone in our journey to ...